Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)
A Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)
Sponsor: Oncology Specialties, Alabama
Terminated
terminated due to lack of accrual.
Other terminated trials from Oncology Specialties, Alabama
More terminations from Oncology Specialties, Alabama
Other Myelodysplastic Syndrome (MDS) trials with similar outcome
Listed as NCT00225992, this PHASE2 trial focuses on Myelodysplastic Syndrome (MDS) and remains terminated or withdrawn. Sponsored by Oncology Specialties, Alabama, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Feb 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oncology Specialties, Alabama
For direct contact, visit the study record on ClinicalTrials.gov .